<DOC>
	<DOCNO>NCT02812121</DOCNO>
	<brief_summary>Hepatitis B virus ( HBV ) -related acute-on-chronic liver failure ( ACLF ) severe disease high mortality . Our previous study demonstrate peripheral infusion bone marrow-derived mesenchymal stromal cell ( MSCs ) weekly 4 time safe improve 24 week survival rate ACLF patient . In study , intend assess safety efficacy umbilical cord blood derive MSCs HBV-related ACLF patient .</brief_summary>
	<brief_title>UC-MSC Infusion HBV-Related Acute-on-Chronic Liver Failure</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<criteria>1 . Patients ACLF—which characterize acute hepatic insult manifest jaundice ( serum total bilirubin ≥ 10×ULN umol/L ) coagulopathy ( international normalize ratio≥ 1.5 prothrombin activity &lt; 40 % ) , complicate within 4 week ascites and/or encephalopathy determine physical examination , patient previously diagnose undiagnosed chronic liver disease ; 2 . Positive serum hepatitis B surface antigen ( HBsAg ) 6 month ; 3 . Endstage liver disease score range 1730 , ; 4.1865 year age . 1 . Serious complication within previous 2 month ( e.g . gastrointestinal bleeding , serious infection ) ; 2 . Concomitant autoimmune disease ; 3 . Superinfection hepatitis virus ; 4 . Important organ dysfunction due liver disease malignancy ; 5 . Pregnancy lactation ; 6 . Liver tumor nodule secondary cirrhosis proven ultrasound , computerize tomography ( CT ) , magnetic resonance ( MR ) imaging ; 7 . Bioartificial liver support therapy ; 8 . Previous liver transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>